Pfizer (PFE) says a Phase III study of its Lyrica drug capsules for restless legs syndrome met...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer (PFE) says a Phase III study of its Lyrica drug capsules for restless legs syndrome met each of its three co-primary endpoints, showing "significant" benefit vs. a placebo and pramipexole. Pfizer says it will continue to analyze the results. PFE +1.1% premarket. (PR)